Cargando…

Predictors of Mortality in Patients with Advanced Cancer—A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: This systematic review and meta-analysis describes the predictors of mortality in patients with advanced cancer. The results indicate that disease stage, lung cancer, ECOG performance status, age, male sex, Charlson comorbidity score, and other multicomponent prognostic models could...

Descripción completa

Detalles Bibliográficos
Autores principales: Owusuaa, Catherine, Dijkland, Simone A., Nieboer, Daan, van der Heide, Agnes, van der Rijt, Carin C. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774229/
https://www.ncbi.nlm.nih.gov/pubmed/35053493
http://dx.doi.org/10.3390/cancers14020328
Descripción
Sumario:SIMPLE SUMMARY: This systematic review and meta-analysis describes the predictors of mortality in patients with advanced cancer. The results indicate that disease stage, lung cancer, ECOG performance status, age, male sex, Charlson comorbidity score, and other multicomponent prognostic models could aid physicians in timely advance care planning. However, combining these predictors in a prognostic model with adequate performance requires more research. ABSTRACT: To timely initiate advance care planning in patients with advanced cancer, physicians should identify patients with limited life expectancy. We aimed to identify predictors of mortality. To identify the relevant literature, we searched Embase, MEDLINE, Cochrane Central, Web of Science, and PubMed databases between January 2000–April 2020. Identified studies were assessed on risk-of-bias with a modified QUIPS tool. The main outcomes were predictors and prediction models of mortality within a period of 3–24 months. We included predictors that were studied in ≥2 cancer types in a meta-analysis using a fixed or random-effects model and summarized the discriminative ability of models. We included 68 studies (ranging from 42 to 66,112 patients), of which 24 were low risk-of-bias, and 39 were included in the meta-analysis. Using a fixed-effects model, the predictors of mortality were: the surprise question, performance status, cognitive impairment, (sub)cutaneous metastases, body mass index, comorbidity, serum albumin, and hemoglobin. Using a random-effects model, predictors were: disease stage IV (hazard ratio [HR] 7.58; 95% confidence interval [CI] 4.00–14.36), lung cancer (HR 2.51; 95% CI 1.24–5.06), ECOG performance status 1+ (HR 2.03; 95% CI 1.44–2.86) and 2+ (HR 4.06; 95% CI 2.36–6.98), age (HR 1.20; 95% CI 1.05–1.38), male sex (HR 1.24; 95% CI 1.14–1.36), and Charlson comorbidity score 3+ (HR 1.60; 95% CI 1.11–2.32). Thirteen studies reported on prediction models consisting of different sets of predictors with mostly moderate discriminative ability. To conclude, we identified reasonably accurate non-tumor specific predictors of mortality. Those predictors could guide in developing a more accurate prediction model and in selecting patients for advance care planning.